Clinical Trials Directory

We are doing this study to learn more about why the right side of the heart doesn't work well in certain heart conditions. We're using heart tissue samples from people with specific heart problems to help us make these important discoveries.

We are doing this study to collect blood and cerebrospinal fluid samples from patients who have breast cancer that has spread to the brain and/or spinal cord. We hope that by analyzing these samples, we can find out how effective different cancer medications are at treating metastases to the leptomeninges (tissue that surrounds the brain and spinal cord). We also want to do genetic testing on these samples to look for cancer mutations that can give us clues about how people might respond to different therapies or which therapies are most likely to be helpful.

We are doing this study to find out if an experimental technology is a safe and effective way to administer treatment for relapsed and/or refractory multiple myeloma (RRMM). We want to know if giving the drug isatuximab as an injection under the skin works as well as giving this same drug as an intravenous (IV) infusion. The drug combination of isatuximab, carfilzomib, and dexamethasone is approved for the treatment of RRMM, but the current standard of care is to give isatuximab through an IV.

If you take part in this study, you will visit the clinic at least ten times over about twenty seven months. Most visits will last two days, but some may take three days if needed. You will be placed into one of two groups by chance. One group will receive the study medicine, and the other group will receive a sham injection, which looks like a real injection but has no medicine.

We will collect health information from medical records and biologic samples at standard of care visits related to your lung transplant. Samples collected may include blood, tissue, and fluids.

We are doing this study to find out if an experimental drug called LY3962673 (the study drug) is a safe and effective option for cancer that has a KRAS G12D mutation. We are also trying to find the best dose level to use.

In this study, people will be placed into one of two groups by chance. One group will receive a new treatment called ronde cel. The other group will receive a CAR T cell treatment that is already approved and chosen by their cancer doctor. The new treatment is made to target two parts of the cancer cells, while current treatments target only one part. People in the study must be able to stay close to the hospital for at least three weeks and come back for follow up visits so doctors can check their health.

We are doing this study to find out if an experimental drug called upadacitinib (the study drug) is a safe and effective option for people with moderate to severe hidradenitis suppurativa (HS) who did not get adequate relief from standard treatment.